title: [Immunological aspects of delayed regeneration of mandibular fractures].
abstract: The level of complications in patients with the mandibular fractures does not have a tendency to the decline. A research purposes is a study of the basic laws of immunological reactions and possibility of optimizing processes osteogenesis by drugs-cytokines at patients with the mandibular fractures with delayed consolidation of bone tissue. 46 patients with the mandibular fractures were observed. The maintenance of cytokines IL - 1β, TNF - α, IL - 4, SICAM-1 in the blood serum, IgA, IgM, IgG in a mouth liquid was probed. It is set that in pathogenesis of delayed consolidation a basic role is played by changes reactivity of organism, which realized in three directions: immunodeficit of humoral immunity, immunodepression of cellular factors of defence, disbalance in functioning of the cytokines system. It is necessary to count the levels of products SICAM-1 and cytokine IL-1β in the blood serum by the diagnostic criteria of bone repair features at patients with the mandibular fractures: development of delayed consolidation of mandibular fragments is accompanied the increase of their parameters at the control group more than in 2 and in 15 times (668,2±10,3 pg/ml and 363,4 ±6,6 pg/ml relatively). Includding in the complex treatment of the mandibular fractures of immunomodulator Ronkoleukin showed clinico-immunological efficiency for the patients with impaired bone repair.
authors.affiliation: SE «Dnipropetrovsk medical academy Ministry of Health of Ukraine», Dnipropetrovsk, Ukraine.
authors.forename: I
authors.initials: I
authors.lastname: Mashchenko
authors.affiliation: SE «Dnipropetrovsk medical academy Ministry of Health of Ukraine», Dnipropetrovsk, Ukraine.
authors.forename: N
authors.initials: N
authors.lastname: Idashkina
authors.affiliation: SE «Dnipropetrovsk medical academy Ministry of Health of Ukraine», Dnipropetrovsk, Ukraine.
authors.forename: A
authors.initials: A
authors.lastname: Gudaryan
mesh_terms: D000328:Adult; D001861:Bone Regeneration / Q000187:drug effects / Q000276:immunology*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D007155:Immunologic Factors / Q000008:administration & dosage; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood / Q000276:immunology; D053583:Interleukin-1beta / Q000097:blood / Q000276:immunology; D015847:Interleukin-4 / Q000097:blood / Q000276:immunology; D008297:Male; D008337:Mandibular Fractures / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D010012:Osteogenesis / Q000187:drug effects / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000276:immunology
chemical_list: D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007155:Immunologic Factors; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; D015847:Interleukin-4